IMMUNOME IMNM 深 沪
等待开盘 11-08 09:30:00 美东时间
14.96
-0.540
-3.48%
华盛通- 最 高15.80
- 今 开15.45
- 成交量 76.53万股
- 最 低 14.64
- 昨 收 15.50
- 总市值 13.02亿
- 52周最高 17.87
- 市盈率 静 --
- 换手率 0.88%
- 52周最低 5.1501
- 委 比 -73.33%
- 总股本 8704.50万
- 历史最高 63.78
- 量 比 0.64
- 振 幅 7.48%
- 历史最低 2.09
- 每 手 1
- 风险率 2.31%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Immunome GAAP EPS of -$0.65
Immunome press release (IMNM): Q3 GAAP EPS of -$0.65. As of September 30, 2025, cash and cash equivalents totaled $272.6 million, including net proceeds of $44.9 million from two transactions under it...
11-07 12:30
Immunome Q3 EPS $(0.65) Misses $(0.58) Estimate
Immunome (NASDAQ:IMNM) reported quarterly losses of $(0.65) per share which missed the analyst consensus estimate of $(0.58) by 12.26 percent. This is a 16.67 percent increase over losses of $(0.78) per share from the
11-07 06:10
Immunome Presented Preclinical Data Showing Its Proprietary Antibody-Drug Conjugate Payload HC74 Overcomes Multiple Mechanisms Of ADC Resistance, Including Payload Efflux And Target Heterogeneity, At The AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics
Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, recently presented preclinical data showing its proprietary antibody-drug conjugate
10-24 00:02
Breaking Down Gilead Sciences: 6 Analysts Share Their Views
Providing a diverse range of perspectives from bullish to bearish, 6 analysts h...
10-09 06:01
Market Whales and Their Recent Bets on GILD Options
Investors with a lot of money to spend have taken a bearish stance on Gilead Sc...
10-03 02:01
美股大行评级 | 潜在涨幅1650.0%！Ascendiant Capital维持GRI Bio"买入"评级，目标价上调至35美元
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从34美元升至35美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.5美元升至7.75美元
09-23 09:52
Goldman Sachs Initiates Coverage On Immunome with Buy Rating, Announces Price Target of $26
Goldman Sachs analyst Salveen Richter initiates coverage on Immunome (NASDAQ:IMNM) with a Buy rating and announces Price Target of $26.
09-22 19:57
What Analysts Are Saying About Gilead Sciences Stock
Gilead Sciences (NASDAQ:GILD) underwent analysis by 5 analysts in the last quar...
09-16 21:01
Where Immunome Stands With Analysts
Immunome (NASDAQ:IMNM) underwent analysis by 4 analysts in the last quarter, re...
09-06 05:02
Craig-Hallum Initiates Coverage On Immunome with Buy Rating, Announces Price Target of $26
Craig-Hallum analyst Adam Vogel initiates coverage on Immunome (NASDAQ:IMNM) with a Buy rating and announces Price Target of $26.
09-05 22:05
